## Leonardo Bandeira E Farias

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7676955/publications.pdf

Version: 2024-02-01

1039880 1281743 12 786 9 11 citations g-index h-index papers 14 14 14 1231 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical aspects of SARS-CoV-2 infection and vitamin D. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 287-291.	2.6	9
2	Occult Renal Calcifications in Patients with Normocalcemic Primary Hyperparathyroidism and Their Association with the Parathyroid Hormone-Vitamin D Axis. International Journal of Endocrinology, 2022, 2022, 1-6.	0.6	0
3	Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism. Bone, 2020, 141, 115583.	1.4	13
4	A Simple Formula to Estimate Parathyroid Weight on 4D-CT, Predict Pathologic Weight, and Diagnose Parathyroid Adenoma in Patients with Primary Hyperparathyroidism. American Journal of Neuroradiology, 2020, 41, 1690-1697.	1.2	6
5	Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism. Radiology, 2019, 291, 469-476.	3.6	101
6	Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate. International Journal of Clinical Pharmacology and Therapeutics, 2019, 57, 163-166.	0.3	7
7	Occult urolithiasis in asymptomatic primary hyperparathyroidism. Endocrine Research, 2018, 43, 106-115.	0.6	28
8	Hyperparathyroidism. Lancet, The, 2018, 391, 168-178.	6.3	371
9	Romosozumab for the treatment of osteoporosis. Expert Opinion on Biological Therapy, 2017, 17, 255-263.	1.4	78
10	Novel Therapies for Postmenopausal Osteoporosis. Endocrinology and Metabolism Clinics of North America, 2017, 46, 207-219.	1.2	25
11	Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 681-689.	1.5	31
12	Primary Hyperparathyroidism. F1000Research, 2016, 5, 1.	0.8	117